S100A16 drives hepatocellular carcinoma by promoting KCNJ8-mediated choline metabolic dysregulation and immunosuppression

Dysregulated choline metabolism is an established metabolic hallmark that fuels hepatic inflammation and tumorigenesis. However, the upstream regulators of this pathway in hepatocellular carcinoma (HCC) are incompletely understood. Here, we identify S100 calcium-binding protein A16 (S100A16) as a pivotal driver of HCC that operates through choline metabolic reprogramming. Integrated transcriptomic and metabolomic analyses revealed a strong association between S100A16 upregulation and choline metabolism dysregulation in HCC. Clinically, S100A16 was significantly elevated in HCC tissues and patient sera, and its high expression correlated with poor overall and disease-free survival. Functionally, S100A16 overexpression promoted, while its knockdown suppressed HCC cell proliferation, invasion, migration, endoplasmic reticulum (ER) stress, and the production of metabolite phosphatidylcholine in vitro. Consistent with this, S100A16 overexpression potentiated tumor growth in subcutaneous xenograft models and enhanced pulmonary metastasis in vivo. Mechanistically, we delineated a novel signaling axis wherein S100A16 activates the Wnt5A/B-β-catenin pathway, leading to the upregulation of potassium inwardly-rectifying channel subfamily J member 8 (KCNJ8), which in turn drives choline metabolism dysregulation and ER stress. Importantly, hepatocyte-specific conditional knockout of S100A16 in a murine HCC model not only attenuated these oncogenic processes but also remodeled the immunosuppressive tumor microenvironment by rescuing CD8 + T cell exhaustion and reducing the infiltration of CD206 + M2-type tumor-associated macrophages. In summary, our study unveils S100A16 as a central regulator of choline metabolism and immunosuppression in HCC, positioning it as a promising diagnostic biomarker and therapeutic target for this cancer.

Authors

Institutions

Publication Details

Journal
Cell Death and Disease
Published
2026-11-18
DOI
https://doi.org/10.1038/s41419-026-09397-3
Primary Topic
Cancer, Lipids, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

S100A16 drives hepatocellular carcinoma by promoting KCNJ8-mediated choline metabolic dysregulation and immunosuppression

Wenqing Dai, 王小银, Bo Huang, Donghua Xu et al.
7 links
Cell Death and Disease
Cancer, Lipids, and Metabolism
article

S100A16 drives hepatocellular carcinoma by promoting KCNJ8-mediated choline metabolic dysregulation and immunosuppression

Wenqing Dai, 王小银, Bo Huang, Donghua Xu, Mingshuai Li, Ying Liu, Junjian Xue, Haobin Zhao, Shushan Yan
article en

Abstract

Dysregulated choline metabolism is an established metabolic hallmark that fuels hepatic inflammation and tumorigenesis. However, the upstream regulators of this pathway in hepatocellular carcinoma (HCC) are incompletely understood. Here, we identify S100 calcium-binding protein A16 (S100A16) as a pivotal driver of HCC that operates through choline metabolic reprogramming. Integrated transcriptomic and metabolomic analyses revealed a strong association between S100A16 upregulation and choline metabolism dysregulation in HCC. Clinically, S100A16 was significantly elevated in HCC tissues and patient sera, and its high expression correlated with poor overall and disease-free survival. Functionally, S100A16 overexpression promoted, while its knockdown suppressed HCC cell proliferation, invasion, migration, endoplasmic reticulum (ER) stress, and the production of metabolite phosphatidylcholine in vitro. Consistent with this, S100A16 overexpression potentiated tumor growth in subcutaneous xenograft models and enhanced pulmonary metastasis in vivo. Mechanistically, we delineated a novel signaling axis wherein S100A16 activates the Wnt5A/B-β-catenin pathway, leading to the upregulation of potassium inwardly-rectifying channel subfamily J member 8 (KCNJ8), which in turn drives choline metabolism dysregulation and ER stress. Importantly, hepatocyte-specific conditional knockout of S100A16 in a murine HCC model not only attenuated these oncogenic processes but also remodeled the immunosuppressive tumor microenvironment by rescuing CD8 + T cell exhaustion and reducing the infiltration of CD206 + M2-type tumor-associated macrophages. In summary, our study unveils S100A16 as a central regulator of choline metabolism and immunosuppression in HCC, positioning it as a promising diagnostic biomarker and therapeutic target for this cancer.

Cell Death and Disease
Weifang Medical University (CN), Weifang People's Hospital (CN)
Natural Science Foundation of Shandong Province
Good health and well-being
Cancer, Lipids, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon